Michael D Kuo

Dr. Michael Kuo is an entrepreneurial physician-scientist, recognized for his innovative work in artificial intelligence, radiogenomics, computational therapeutic antibody design, and oncologic biomarker discovery. Dr. Kuo’s work is patented in drug and cancer biomarker discovery. He is sought and has served as, a member of several private, public and commercial advisory committees and Boards.

His academic positions include Professorships at the University of Hong Kong, University of California- Los Angeles (UCLA), University of California-San Diego (UCSD), and Stanford University, where he also practiced diagnostic and interventional radiology, and served in leadership roles establishing UCLA’s Rad-Path Integrated Diagnostics program and Hong Kong’s Medical AI Laboratory Program -- interdisciplinary programs bridging artificial intelligence and translational medicine.

He is consistently recognized for his scientific work, winning the Radiological Society of North America (RSNA) Alexander R. Margulis Award for best scientific paper, and the Gary Becker Young Investigator Award from the Society of Interventional Radiology. Highly published in top journals, including Nature Biotechnology (IF 54.9), Hepatology (IF 17.4), and Radiology (IF 29), Dr. Kuo has published over 80 scientific papers. An established speaker at international venues, he is frequently invited to present, with over 175 scientific talks across the globe.

Dr. Kuo actively works to progress the fields of developing technology. He co-founded several companies based on applications of his work: 1) Confluence Life Sciences – a small molecule rational drug discovery company focused on inflammation and oncology, and 2) Confluence Discovery Technologies, a contract research organization for pharmaceutical companies, each respectively acquired by Aclaris Therapeutics (NASDAQ: ACRS) and Lymbus Oncology. Other start-up companies have focused on AI generated therapeutic high affinity antibodies, radiogenomics-based cancer immunotherapy predictive biomarkers, and remote-sensing based AI solutions for environmental remediation.

Education

• Doctor of Medicine (M.D.) Baylor College of Medicine
• Bachelor's degree University of Missouri-Kansas City
• Northwestern University